Literature DB >> 17915574

Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor.

A Martinuzzi1, A Liava, E Trevisi, L Antoniazzi, M Frare.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17915574      PMCID： PMC2949319     

Source DB:  PubMed          Journal:  Acta Myol        ISSN： 1128-2460


× No keyword cloud information.
  7 in total

1.  The ACE gene and muscle performance.

Authors:  A G Williams; M P Rayson; M Jubb; M World; D R Woods; M Hayward; J Martin; S E Humphries; H E Montgomery
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

2.  The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.

Authors:  John Vissing; Ronald G Haller
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

3.  Effect of ramipril on the incidence of diabetes.

Authors:  Jackie Bosch; Salim Yusuf; Hertzel C Gerstein; Janice Pogue; Patrick Sheridan; Gilles Dagenais; Rafael Diaz; Alvaro Avezum; Fernando Lanas; Jeffrey Probstfield; George Fodor; Rury R Holman
Journal:  N Engl J Med       Date:  2006-09-15       Impact factor: 91.245

4.  Aerobic conditioning: an effective therapy in McArdle's disease.

Authors:  Ronald G Haller; Phil Wyrick; Tanja Taivassalo; John Vissing
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

5.  Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training.

Authors:  H Montgomery; P Clarkson; M Barnard; J Bell; A Brynes; C Dollery; J Hajnal; H Hemingway; D Mercer; P Jarman; R Marshall; K Prasad; M Rayson; N Saeed; P Talmud; L Thomas; M Jubb; M World; S Humphries
Journal:  Lancet       Date:  1999-02-13       Impact factor: 79.321

6.  Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.

Authors:  A H Danser; M A Schalekamp; W A Bax; A M van den Brink; P R Saxena; G A Riegger; H Schunkert
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

7.  Phenotype modulators in myophosphorylase deficiency.

Authors:  Andrea Martinuzzi; Elena Sartori; Marina Fanin; Annachiara Nascimbeni; Lucia Valente; Corrado Angelini; Gabriele Siciliano; Tiziana Mongini; Paola Tonin; Giuliano Tomelleri; Antonio Toscano; Luciano Merlini; Laurence A Bindoff; Stefano Bertelli
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422
  7 in total
  6 in total

Review 1.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  Rosaline Quinlivan; Andrea Martinuzzi; Benedikt Schoser
Journal:  Cochrane Database Syst Rev       Date:  2014-11-12

Review 2.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 3.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

Review 4.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26

5.  Genotype-phenotype correlation in Pompe disease, a step forward.

Authors:  Paola De Filippi; Kolsoum Saeidi; Sabrina Ravaglia; Andrea Dardis; Corrado Angelini; Tiziana Mongini; Lucia Morandi; Maurizio Moggio; Antonio Di Muzio; Massimiliano Filosto; Bruno Bembi; Fabio Giannini; Giovanni Marrosu; Miriam Rigoldi; Paola Tonin; Serenella Servidei; Gabriele Siciliano; Annalisa Carlucci; Claudia Scotti; Mario Comelli; Antonio Toscano; Cesare Danesino
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

Review 6.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review.

Authors:  Carlota Pascoal; Sandra Brasil; Rita Francisco; Dorinda Marques-da-Silva; Agnes Rafalko; Jaak Jaeken; Paula A Videira; Luísa Barros; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2018-11-28       Impact factor: 4.123
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.